1. Pathophysiology: Infiltration vs. Vesicant Extravasation
Vascular access complications represent the most frequent adverse event during intravenous therapy. Infiltration refers to the unintentional leakage of non-vesicant solutions into surrounding subcutaneous tissue, whereas extravasation involves vesicant medications capable of producing cellular apoptosis, severe ulceration, and full-thickness tissue necrosis.
Vesicant antineoplastic drugs fall into two pathophysiological classifications:
- DNA-Binding Vesicants (Anthracyclines & Alkylating Agents): Doxorubicin, Daunorubicin, Epirubicin, and Mitomycin-C bind to cellular DNA, causing cell death. As dead cells lyse, the persistent drug is released into neighboring healthy tissue, creating progressive, chronic, non-healing ulcerations that often require surgical excision.
- Non-DNA-Binding Vesicants (Plant Alkaloids & Taxanes): Vincristine, Vinblastine, Vinorelbine, and Paclitaxel disrupt microtubule dynamics. While causing severe local blistering, edema, and tissue sloughing, they are metabolized and cleared more rapidly and do not persist indefinitely in the extracellular matrix.
2. INS Staging Scale & Classification Matrix
The Infusion Nurses Society (INS) 2024 Standards of Practice define a 5-tier clinical infiltration and extravasation staging scale based on gross edema measurements, skin temperature, and neurovascular assessment.
| Grade | Clinical Presentation | Gross Edema | Skin Characteristics | Mandatory Clinical Action |
|---|---|---|---|---|
| 0 | No clinical symptoms; intact skin sensation | 0 cm | Normal color, warm to touch, brisk capillary refill | Continue Routine Monitoring |
| 1 | Skin blanched; edema < 1 inch in any direction; cool to touch; with or without pain | < 2.5 cm | Blanched, local coolness, mild tenderness | Halt Infusion · Elevate |
| 2 | Skin blanched; edema 1–6 inches; cool to touch; with or without pain | 2.5 – 15 cm | Blanched, distinct cool demarcation, aching pain | Aspirate · Discontinue PIV |
| 3 | Skin blanched, translucent; gross edema > 6 inches; cool; mild-moderate pain; possible numbness | > 15 cm | Translucent, taut, cool, decreased pulse distally | Physician Consult · Cold Pack |
| 4 | Skin blanched, translucent; skin tight, leaking; discolored, bruised, swollen; gross edema > 6 in; deep pitting edema; circulatory impairment; moderate-severe pain; ANY vesicant extravasation | > 15 cm (deep) | Discolored / cyanotic / blistering, ulceration risk, capillary refill > 3s | CODE VESICANT · Specific Antidote |
3. Pharmacological Antidote Administration Protocols
Specific pharmacological antidotes are indicated for distinct vesicant drug categories. Timely administration within 6 hours of extravasation is critical to neutralize tissue damage.
| Drug Class | Representative Vesicants | First-Line Antidote & Dosage | Thermal Protocol |
|---|---|---|---|
| DNA-Binding Anthracyclines | Doxorubicin, Daunorubicin, Epirubicin | Dexrazoxane IV: Day 1: 1000 mg/m², Day 2: 1000 mg/m², Day 3: 500 mg/m² (initiate within 6 hours) | Dry Cold Pack: 15–20 min q4h x 48h |
| Non-DNA-Binding Alkaloids | Vincristine, Vinblastine, Vinorelbine | Hyaluronidase SC: 150–300 U (1–2 mL) divided into 0.2 mL circular subcutaneous blebs around margin | Dry Warm Pack: 15–20 min q4h x 48h (promotes dispersion) |
| Taxanes | Paclitaxel, Docetaxel | Hyaluronidase SC (150–300 U) considered per institutional protocol | Dry Cold Pack: 15–20 min q4h x 48h |
| Alkylating Agents | Cisplatin (>20 mL / >0.5 mg/mL), Mechlorethamine | Sodium Thiosulfate (1/6 M): 2 mL injected SC per estimated 1 mL extravasated | Dry Cold Pack: 15–20 min q4h x 48h |